NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Biological: PROSTVAC-V
Biological: PROSTVAC-F
Drug: MSB0011359C (M7824)
Biological: CV301

First Posted Date: 2017-10-20

Last Posted Date: 2024-12-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT03315871

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Phase 1

Completed

Conditions: Recurrent High Grade B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma

Interventions: Biological: Mogamulizumab
Biological: Pembrolizumab

First Posted Date: 2017-10-16

Last Posted Date: 2023-09-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT03309878

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 5 locations

Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study

Active, not recruiting

Conditions: Human Papillomavirus Infection
Human Papillomavirus-Related Malignant Neoplasm

Interventions: Procedure: Biospecimen Collection
Other: Questionnaire Administration

First Posted Date: 2017-10-13

Last Posted Date: 2025-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 991

Registration Number: NCT03309033

Locations: 🇨🇷
Agencia Costarricense de Investigaciones Biomédicas (ACIB), Liberia, Guanacaste, Costa Rica

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Advanced Merkel Cell Carcinoma
Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8
Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Metastatic Merkel Cell Carcinoma
Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8
Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8

Interventions: Biological: Pembrolizumab
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2017-10-09

Last Posted Date: 2025-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT03304639

Locations: 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
🇺🇸
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States

and more 253 locations

Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer

Phase 2

Terminated

Conditions: Gastrointestinal Cancer
Pancreatic Cancer
Ovarian Cancer
Melanoma
Breast Cancer

Interventions: Biological: Peptide loaded dendritic cell vaccine

First Posted Date: 2017-10-04

Last Posted Date: 2019-12-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1

Registration Number: NCT03300843

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

Recruiting

Conditions: Human Immunodeficiency Virus
Kaposi's Sarcoma
Castleman's Disease
Viral-Associated Cancer

First Posted Date: 2017-10-04

Last Posted Date: 2025-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 280

Registration Number: NCT03300830

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer

Phase 1

Active, not recruiting

Conditions: Lung Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: MUC1 Peptide-Poly-ICLC Vaccine

First Posted Date: 2017-10-04

Last Posted Date: 2025-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT03300817

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Phase 2

Active, not recruiting

Conditions: Atypical Hyperplasia
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

Interventions: Drug: Exemestane
Other: Laboratory Biomarker Analysis
Other: Pharmacokinetic Study
Other: Questionnaire Administration

First Posted Date: 2017-10-03

Last Posted Date: 2025-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT03300557

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States

Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

Phase 1

Terminated

Conditions: Locally Advanced Rectal Adenocarcinoma
Stage IVA Rectal Cancer AJCC v7
Stage IIIA Rectal Cancer AJCC v7
Stage IIIB Rectal Cancer AJCC v7
Stage IV Rectal Cancer AJCC v7
Stage IVB Rectal Cancer AJCC v7
Metastatic Rectal Adenocarcinoma
Rectal Adenocarcinoma
Stage III Rectal Cancer AJCC v7
Stage IIIC Rectal Cancer AJCC v7

Interventions: Drug: Capecitabine
Drug: Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin
Radiation: Radiation Therapy
Biological: Talimogene Laherparepvec

First Posted Date: 2017-10-03

Last Posted Date: 2024-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT03300544

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers

Phase 1

Completed

Conditions: Colorectal Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Dolcanatide
Other: Placebo Administration
Other: Questionnaire Administration

First Posted Date: 2017-10-03

Last Posted Date: 2021-06-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT03300570

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy